PETRI DISH PERSPECTIVES

Send us Fan Mail In this episode of Petri Dish Perspectives , we unpack the strategy and scientific conviction behind ARCH Venture Partners , the venture firm that has quietly helped build some of the most transformative companies in modern biotechnology. From early bets on platform technologies like gene editing and mRNA to backing next-generation leaders such as Juno , Editas Medicine , Beam The...

Send us Fan Mail In this episode of Petri Dish Perspectives , we explore the fascinating evolution of Otsuka Holdings , a company that defies traditional pharmaceutical stereotypes. From its origins in Japan as a chemical and nutrition-focused business to becoming a global biopharma innovator, Otsuka has built its reputation by targeting complex and often misunderstood disease areas such as psychi...

Send us Fan Mail What if medicine could fix disease at its source… by rewriting the genetic code itself? In this episode of Petri Dish Perspectives , we dive into the incredible story of gene therapy , one of the most ambitious and transformative frontiers in modern medicine. From early scientific discoveries about DNA and viral delivery systems, to heartbreaking clinical setbacks that nearly shut...

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for January 2026! This month was dominated by a surge in Eli Lilly's deals, partnerships, etc.  🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bu...

Send us Fan Mail What does it take to spend decades chasing one of medicine’s hardest problems while the rest of the industry walks away? In this episode, we explore the remarkable story of Eisai , the Japanese pharmaceutical company that built its global identity around Alzheimer’s disease. From its founding during World War II and early commitment to ethical medicine, to the blockbuster success...

Send us Fan Mail Flagship Pioneering doesn’t wait for scientific breakthroughs. It builds them. In this episode, we dive deep into the origin story of one of the most influential venture creation firms in biotech and the mind behind it, Noubar Afeyan. From his early life shaped by uncertainty to the founding of a firm that treats biology like an engineering discipline, we explore how Flagship rede...

Send us Fan Mail Biogen is one of the most influential and controversial companies in modern biotechnology. Founded in the late 1970s by Nobel-level scientists who believed recombinant DNA would redefine medicine, Biogen helped turn neurology into a commercial field long before most pharma companies dared to enter it. In this episode, we trace Biogen’s full journey, from its academic origins and t...

Send us Fan Mail Theranos promised to revolutionize healthcare with a single drop of blood and became one of the most infamous failures in biotech history.  In this episode, we trace the full rise and fall of Elizabeth Holmes and Theranos, from its founding in 2003 to its dramatic collapse and criminal convictions nearly two decades later. We explore how ambition, secrecy, and Silicon Valley mytho...

Send us Fan Mail Novo Nordisk’s rise is one of the most extraordinary stories in modern medicine. What began in 1920s Denmark as a response to a fatal disease evolved into a company that reshaped how the world treats diabetes, obesity, and metabolic illness. In this episode, we trace Novo Nordisk’s journey from the discovery of insulin and a decades-long rivalry between two Danish labs, to a landm...

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for December 2025! This month was dominated by a surge in M&A activity and licensing deals. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau...

Send us Fan Mail Before there were blockbuster drugs, clinical trials, and biotech startups, there was… dye. In this episode of Petri Dish Perspectives , we explore one of the most overlooked origin stories in modern medicine: how 19th-century chemical dye companies laid the foundation for today’s pharmaceutical giants. From coal tar chemistry and synthetic pigments to the birth of industrial drug...

Send us Fan Mail In this episode, we explore the evolution of Astellas Pharma, from the merger of two century-old Japanese firms into a global biopharmaceutical powerhouse. We trace how a culture of disciplined research led to breakthrough medicines like Prograf, transformed transplant medicine, and later to Xtandi, a prostate cancer therapy born from academic insight and refined through global co...

Send us Fan Mail In this episode of Petri Dish Perspectives , we dive deep into the remarkable evolution of Novartis , one of the world’s most influential and scientifically ambitious pharmaceutical companies. From its 18th-century dye-making origins to its modern dominance in gene therapy, oncology, and complex biologics, Novartis has become a case study in strategic reinvention. We explore the c...

Send us Fan Mail Can a machine discover a cure faster than a scientist? Welcome to the revolutionary world of Recursion Pharmaceuticals , the pioneering TechBio company determined to solve biology using AI and industrial automation. In this deep-dive, we explore how Recursion replaced slow, human-biased research with the Recursion OS , a closed-loop platform that generates massive, proprietary bio...

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for November 2025! This month was dominated by a surge in M&A activity, with high-profile bidding wars!  🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspe...

Send us Fan Mail Unlock the future of immunotherapy. For decades, traditional antibody drugs were limited to tagging a single target. Now, meet the Bispecific Antibody (BsAb) : a revolutionary molecule engineered to simultaneously grab two different targets, acting as a molecular "handcuff" to drag your immune system's most powerful killer, the T cell, directly to the cancer cell. I...

Send us Fan Mail In this episode of Petri Dish Perspectives: , we dive into one of the most dramatic biotech stories of the decade: the rise of Metsera , the VC-backed obesity startup that triggered a rare billion-dollar bidding war between two pharma giants, Pfizer and Novo Nordisk. We explore how Metsera quietly emerged from Flagship’s venture creation engine, how its science positioned it as a...

Send us Fan Mail In this episode of Petri Dish Perspectives , we dive into the untold story of Charles River Laboratories , the quiet giant behind nearly every major drug you’ve ever heard of. From its origins on the banks of Massachusetts’ Charles River, where Dr. Henry Foster began breeding lab rats to support post-war research, to its evolution into a global scientific infrastructure company ,...

Send us Fan Mail In this episode of Petri Dish Perspectives: Biotech Unleashed , host Manead dives into the remarkable story of Regeneron Pharmaceuticals , from its humble beginnings in Tarrytown to becoming one of the world’s leading biotech innovators. Discover how founders Leonard Schleifer and George Yancopoulos turned early failure into scientific triumph with breakthrough drugs like Eylea ,...

Send us Fan Mail What if the cure for cancer or the key to mental health, wasn’t hidden in a new drug, but in data itself? In this episode of Petri Dish Perspectives , we uncover the story of Tempus AI , the company turning raw medical information into lifesaving insight. Founded by Eric Lefkofsky , the entrepreneur behind Groupon, Tempus began as a deeply personal mission to bring clarity to canc...

Send us Fan Mail What if the secret engine driving modern drug discovery wasn’t in Boston or Basel, but in Shanghai? In this episode of Petri Dish Perspectives: Biotech Unleashed , host Manead dives deep into the rise of WuXi AppTec , a company that redefined how the world develops medicine. We explore its fascinating journey, from a humble chemistry startup founded by Dr. Ge Li to a global R&...

Send us Fan Mail From a small pharmacy in Massachusetts to a $100 billion healthcare empire, CVS Health has redefined what it means to be a pharmacy. In this episode of Petri Dish Perspectives: Biotech Unleashed , host Manead dives into CVS’s fascinating evolution, from its early days as Consumer Value Store to its bold moves acquiring Aetna and transforming into a fully integrated healthcare prov...

Send us Fan Mail From a lizard’s venom to Hollywood’s favorite weight-loss trend, this episode of Petri Dish Perspectives: Biotech Unleashed dives deep into the fascinating journey of GLP-1 agonists.  Discover how scientists uncovered a gut hormone that revolutionized diabetes care, led to the creation of Ozempic and Mounjaro, and sparked a cultural movement around body image and health. We’ll tra...

Send us Fan Mail What if you could silence disease at its genetic root? That was the bold promise behind RNA interference (RNAi), one of the most groundbreaking scientific discoveries of the 21st century. In this episode, we dive into the story of Alnylam Pharmaceuticals , from its founding by a powerhouse team of Nobel laureates, pioneering scientists, and biotech visionaries, to its transformati...

Send us Fan Mail From its humble beginnings in 1781 as a family-run herbal medicine shop in Osaka to becoming one of the world’s top 10 pharmaceutical companies, Takeda’s story is one of resilience, reinvention, and bold transformation. In this episode of Petri Dish Perspectives: Biotech Unleashed , host Manead unpacks Takeda’s 240-year journey, from the vision of founder Chobei Takeda, through th...